▲ See the end of the article for detailed schedule ▲

Veterinary vaccine is one of the most effective and economical strategies to prevent and control livestock and poultry infectious diseases, and it is also the most important part of veterinary biological products in China. This paper counts 8 listed companies related to veterinary vaccines in A shares, including China Animal Husbandry Co., Ltd., Biology Co., Ltd., Rip Biology, Pleco, Keqian Biology, Yongshun Biology, Shenlian Biology and Haili Biology . It mainly introduces the general situation of the companies, the main veterinary vaccine products listed and related research pipelines.

Table 1: Total market capitalization and revenue of 8 A- share veterinary vaccine-related listed companies

1. Zhongmu Industrial Co., Ltd.

China Animal Husbandry Co., Ltd. was established in 1998 and is a large-scale comprehensive agricultural central enterprise under the direct management of the State-owned Assets Supervision and Administration Commission of the State Council, China Agricultural Development Group Co., Ltd. In January 1999, the company was listed on the Shanghai Stock Exchange under the stock code 600195. The company's main business scope covers the core business of veterinary biological products, veterinary drugs, feed and feed additives, raw material trade and other key links in the upstream of the supply chain of the animal husbandry industry chain. It is an important component of my country's veterinary drug industry and feed industry, and it is also highly pathogenic avian influenza., Foot-and-and-mouth disease and other major animal disease vaccines designated manufacturers.

among them, veterinary biological products are the core of the company, accounting for about 20% of revenue , gross profit margin is about 50%, contributes nearly 50% of gross profit . At present, the company has Lanzhou Biopharmaceutical Factory, Chengdu Pharmaceutical Factory, Jiangxi Biopharmaceutical Factory and Zhongpu Biopharmaceutical production base. Its products mainly include poultry vaccine, livestock vaccine and pet vaccine , specifically including highly pathogenic avian influenza vaccine, foot-and-mouth disease vaccine, porcine circovirus inactivated vaccine, porcine pseudorabies live vaccine, rabies inactivated vaccine and other conventional veterinary vaccine products and diagnostic preparations. The company is a veterinary vaccine production enterprises in the product variety, production capacity and output of the larger enterprises.

Table 2: Biopharmaceutical Production Base of China Animal Husbandry Co., Ltd.

Table 3: Combing of Main Veterinary Vaccine Products in China Animal Husbandry

in addition, it is worth noting that the company poultry seedling advantage is stable , its Qian Yuanhao is committed to the prevention and control of poultry infectious diseases, the main business is the research and development, production, sales and technical services of poultry biological products, the main products are multi-species of poultry vaccines and a small amount of livestock vaccines. The company has made outstanding contributions in the national prevention and control of major animal diseases such as avian influenza, chicken Marek's disease, and foot-and-mouth disease.

Figure 1: Introduction of some poultry products of Qianyuan Hao

2. Tianjin Rip Biotechnology Co., Ltd.

Rip Bio was established in 1998. It is a four-in-one manufacturer and service provider of biological vaccines, pharmaceutical raw materials, pharmaceutical preparations and feed additives in China. In 2010, the company was officially listed on the Shenzhen Stock Exchange, stock code 300119. As of the end of June 2023, the company has 20 branches (subsidiaries), 11 large-scale production bases, and 96 production lines, and more than 500 veterinary drug product approval numbers and feed additives have been filed, involving pigs, chickens, waterfowl, cattle, and Sheep and pet drugs, vaccines, disinfectants, cleaning agents and functional additives are one of the largest veterinary drug companies with the most complete product categories in China, it is also a major national animal disease prevention and control vaccine manufacturer.

the company has a complete product category, has 534 products, including 119 kinds of biological products . The products have basically covered the major animal diseases faced by the livestock and poultry breeding industry, and have a leading edge in the frontier fields such as genetic engineering vaccines and polyvalent vaccines . The company's poultry vaccine is at the front end of the industry , with a wide range of related products, including recombinant avian influenza virus (H5 + H7) trivalent inactivated vaccine, H9 subtype avian influenza vaccine product line series. Animal vaccine plate, in the blue ear, ring, swine fever and other multi-pipeline also have products.

Table 4: Rip Bio Focus Vaccine Products

In addition, the company is also expanding the field of pet vaccines , for dogs, cats and other pets must be vaccinated, the company has formed a product development matrix aimed at import substitution, to fill the domestic gap. On January 8, 2024, Rip Bio held China's first domestic cat triple vaccine "Rui Meow Shu" listing conference, and on January 18, the first to obtain the Ministry of Agriculture and Rural Affairs approval number officially listed, launched the cat triple vaccine domestic substitution of the first shot . It is worth noting that also on January 8, Rip Biology and Shenji Biology jointly signed the "Cooperative Development Agreement for Feline HCPC Quadruple mRNA Vaccine" to jointly research and develop feline rhinotracheitis, calicivirus disease, panleukopenia and feline chlamydia quadruple mRNA vaccine. In addition, according to the company's investor interaction platform in January this year, the company's canine quadruple vaccine has completed clinical trials in the first half of 2023 and is currently in the stage of applying for registration of a new veterinary drug certificate.

3. Jinyu Biotechnology Co., Ltd.

Biological Co., Ltd. was established in 1993, mainly engaged in the research and development, production and sales of veterinary biological products. In 1998, the company was listed on the main board of the Shanghai Stock Exchange under the stock code 600201. The company's product range covers pig, poultry, ruminant and pet four series of more than 100 kinds of animal vaccines . The company has foot-and-mouth disease, highly pathogenic avian influenza and brucellosis three compulsory immunization vaccines designated by the Ministry of Agriculture production qualifications, research and development technology, product quality and biosafety to maintain the domestic leading level.

the company has five core subsidiaries, of which four are involved in veterinary vaccines, namely Jinyu Baoling (mainly producing foot-and-mouth disease vaccines, ruminant vaccines, etc.), Yangzhou Youbang (mainly producing genetically engineered vaccines for pigs, poultry and waterfowl vaccines, etc.), Liaoning Yikang (mainly producing bird flu vaccines), and Jinyu Gongli (mainly producing pet vaccines and pet supplies).

Figure 2: Bio-Share Core Subsidiaries

It is worth noting that the company is the first domestic veterinary drug enterprise that can simultaneously carry out foot-and-mouth disease, African swine fever, brucellosis vaccine research and development related experimental activities. Relying on the National Engineering Laboratory of Veterinary Vaccine, the Key Laboratory of Ruminant Biological Products of the Ministry of Agriculture and the Three-level Laboratory of Animal Biosafety (ABSL-3). In addition, the company has dozens of R & D platforms and multiple types of vaccine R & D technologies. The company has established dozens of research and development platforms such as virus vaccine and technology platform, bacteria and protein expression platform, genetic engineering platform, ruminant vaccine platform, brucellosis vaccine platform, African swine fever vaccine integrated development platform, pet vaccine platform and so on, and has been continuously optimized. At present, we have mastered the research and development technology of multi-type vaccines, and the research and development pipeline covers subunit vaccines, gene deletion vaccines, vector vaccines, nucleic acid vaccines, inactivated vaccines, live attenuated vaccines, synthetic peptide vaccines and other vaccines.

Figure 3: Bio-Share R & D Platform

The company's vaccine products include swine vaccines, such as swine foot-and-mouth disease vaccine, pseudorabies vaccine, circovirus vaccine, blue ear disease vaccine, etc.; ruminant vaccines, such as foot-and-mouth disease vaccine, brucellosis vaccine, etc.; poultry vaccines, such as chicken Newcastle disease vaccine, avian influenza vaccine, duck fever vaccine, etc.; pet vaccines, such as dog rabies vaccine (Canine Health).

Table 5: Bio Share Key Products

in the development of new vaccines, the company's swine foot-and-mouth disease VLP vaccine, swine fever E2 protein subunit vaccine, pig pseudorabies gene deletion inactivated vaccine and other 10 vaccines in the new veterinary drug registration stage, 2024 is expected to make progress. In addition, the company is also accelerating the research and development of polyvalent vaccines. At present, two projects are in the registration stage of new veterinary drugs, one project has obtained clinical trial approval, three projects have entered the clinical trial application stage, and five projects are in the laboratory research and development stage.

Table 6: Research Progress of Bio-Share Multi-Seedling Products

in the pet vaccine sector, the company has obtained the canine quadruple vaccine, cat quadruple vaccine clinical trial approval, the canine triple vaccine is in the clinical trial stage, the cat triple vaccine has been submitted for emergency review, the new pet osteoarthritis products, cat panleukopenia treatment of drugs research and development work is progressing smoothly.

Table 7: Progress in R & D of Bio-Share Pet Vaccine Products

4. Pleco Bioengineering, Inc.

Pleco was established in 2002, is a research and development, production, management of veterinary biological products and pharmaceutical-based high-tech enterprises. It has 7 wholly-owned subsidiaries of Luoyang Huizhong Biotechnology Co., Ltd., Luoyang Huizhong Veterinary Drug Co., Ltd., Henan Xinzheng Bioengineering Co., Ltd., Luoyang Zhongke Science Park Co., Ltd., Placo (Nanjing) Biotechnology Co., Ltd., Luoyang Huizhong Animal Health Care Co., Ltd. and Luoyang Lechong Health Technology Co., Ltd. In May 2015, the company was successfully listed on the main board of the Shanghai Stock Exchange with the stock code 603566.

The company has a complete range of products, covering animal vaccines, antibodies, high-tech preparations of chemical drugs, Chinese veterinary drugs, disinfectants and other series of products. In terms of animal vaccines, the company currently has the industry-leading pig, poultry series of market-oriented genetic engineering vaccines and multi-linked multivalent vaccines , basically covering the major animal diseases faced by the livestock and poultry breeding industry.

specifically, the company's vaccines for pigs include two-combination inactivated vaccine of pig branch branch, subunit vaccine of pig ring (yuan kexin), recombinant baculovirus inactivated vaccine of swine fever virus E2 protein (wenkejing), two-combination inactivated vaccine of pig infectious gastroenteritis-porcine epidemic diarrhea and live vaccine (huifenan and huifenning), two-price inactivated vaccine of hemophilus parasuis (funis), etc, used to prevent porcine circovirus disease, swine mycoplasma pneumonia, swine fever, Haemophilus parasuis and other common swine diseases; poultry vaccine products include new tributary (Re-9 strain) triple inactivated vaccine, new tributary method (rVP2 protein) quadruple inactivated vaccine, new flow method (rVP2 protein) triple inactivated vaccine and other products, used to prevent Newcastle disease, infectious bronchitis, bursa of Fabricius and other common diseases.

Table 8: Placo Vaccine Products Combed

In terms of independent innovation, through years of technology accumulation, the company has built a complete reverse genetics technology, prokaryotic expression technology, eukaryotic cell expression technology, polyvalent vaccine technology, bacterial high-density fermentation technology, antigen concentration and purification technology and other technology platforms, with the development of subunit vaccines, nucleic acid vaccines, live vector vaccines, gene deletion vaccines and other series of genetic engineering vaccines.

In terms of research pipelines, such as porcine pseudorabies vaccine, the company is actively promoting the approval of live vaccine products for epidemic strains: as of mid -2023, the company's self-developed live vaccine for porcine pseudorabies epidemic strains (HN1201-R1 strains) isWill enter the new veterinary drug registration review test stage, is expected to become the first approved pig pseudo-rabies epidemic strain live vaccine. At the same time, the company many new pseudorabies products are also in reserve , and the overall research and development process is steadily advancing.

Table 9: Pleco Pseudorabies Virus Vaccine Development Pipeline Overview

in terms of pet vaccine, pleco's cat triple inactivated vaccine has passed the emergency evaluation of the Ministry of agriculture and rural areas . the company said that it has prepared sufficient production capacity for the vaccine and can be put on the market after applying for and obtaining the temporary veterinary drug product approval number according to relevant regulations. In addition, the company's vaccine for dogs is also in development.

Figure 4: Pleco Pet Vaccine Pipeline and Stage Overview

5. Wuhan Keqian Biological Co., Ltd.

Keqian Biology was established in 2001, focusing on the research and development, production and sales of veterinary biological products and technical services for animal epidemic prevention. In 2019, the company's first pet vaccine product "Kewangyou" successfully launched. In 2020, the Company was successfully listed on the Shanghai Stock Exchange's CRE Board under the stock code 688526.

At present, the company can produce 56 veterinary biological products, and is one of the most abundant products in the veterinary biological products industry in China. The company's main products are non-national mandatory immunization of pig vaccines and poultry vaccines, especially non-strong immunity of pig vaccines based , is the domestic pig pseudorabies vaccine, pig gastroenteritis/diarrhea two vaccine leading . It is worth noting that according to the statistics of China Veterinary Drug Association, the market growth of non-state compulsory immunization veterinary biological products in China is significantly faster than that of national compulsory immunization veterinary biological products. After 2015, the market share of non-forced varieties gradually increased, from 40 per cent in 2015 to 64.6 per cent in 2021.

Table 10: Market Share and Ranking of Key Products of Keqian Bio, 2020-2021

specifically, the company's pig vaccine revenue accounts for more than 90%, and its main products include pig pseudorabies live vaccine (HB98 strain), pig pseudorabies heat-resistant protective agent live vaccine (HB2000 strain), pig infectious gastroenteritis, pig epidemic diarrhea dual live vaccine (WH1R strain + AJ1102-R strain), pig pseudorabies inactivated vaccine, porcine circovirus type 2 inactivated vaccine (WH strain), etc; poultry vaccine revenue accounted for less than 5%, the main products include chicken Marek's disease live vaccine (814 strains), chicken Newcastle disease/infectious bronchitis dual live vaccine (LaSot strain + H52 strain), etc.; Pet vaccine revenue accounted for a relatively small proportion, the main products include canine distemper/canine parainfluenza/canine adenovirus/canine parvovirus disease quadruple live vaccine and rabies inactivated vaccine (SAD strain).

Table 11: Combing of Key Products of Pre-Kotech Biology

In terms of research pipelines, the company has prospectively laid out two research and development routes for non-plague vaccines, including subunit vaccines and live vector vaccines, and the live vector vaccines have been submitted for emergency evaluation. In addition, in poultry vaccines, ruminant vaccines, pet vaccines, the company has laid out two or three key products in research.

table 12: combing of pre-scientific biological key products under research

6. Guangdong Yongshun Biopharmaceutical Co., Ltd.

Yongshun Biological was established in 2002. It is a biomedical enterprise integrating R & D, production, sales and technical services of veterinary biological products. In November 2021, Yongshun Bio successfully landed on the North Stock Exchange and became one of the first listed companies on the North Stock Exchange in China, with the securities code 839729.

the company has a complete range of products, covering about 30 varieties of pig vaccines and poultry vaccines , including monovalent seedlings, polyvalent seedlings, polyvalent seedlings and polyvalent seedlings. In the sub-sector, Yongshun Bio is the leading enterprise in the field of swine fever vaccine . The company's core products outstanding, successfully developed animal vaccine generation cell production technology and obtained the national invention patent authorization, the first in the domestic use of generation cells to produce efficient and safe new swine fever live vaccine (generation cell source), to fill the domestic use of generation cells to produce swine fever live vaccine blank. In addition, the company's other pig vaccine products such as swine fever, swine erysipelas, pig multi-kill pasteurellex triple live vaccine national market share are also ranked in the forefront.

Table 13: Combing of Yongshun Bio-listed Products

In order to open up different markets, Yongshun Bio currently has a number of new veterinary drug projects under development, covering pet vaccines, pig vaccines, poultry vaccines, etc. According to public information, in the company's current research projects, there are 9 new products that are being registered for new veterinary drugs; 11 new products that have been approved for clinical trials and clinical research; new products that are undergoing laboratory research and pilot studies There are 6.

7. Shenlian Biopharmaceutical (Shanghai) Co., Ltd.

Shenlian Biology was established in June 2001. It is a national high-tech enterprise specializing in the research and development, production and sales of veterinary biological products, and a foot-and-mouth disease vaccine manufacturer designated by the Ministry of Agriculture and Rural Affairs. In October 2019, the company was successfully listed on the Shanghai Stock Exchange. The company has two major veterinary drug GMP production bases in Shanghai and Lanzhou, and is a designated manufacturer of foot-and-mouth disease vaccine in the Ministry of Agriculture and Rural Affairs.

The company focuses on animal diseases that seriously endanger the safety of the aquaculture industry and have the largest demand for vaccines. The company's main products are series of foot-and-mouth disease vaccine, porcine ring virus type 2 subunit vaccine (recombinant baculovirus OKM strain) and a series of veterinary diagnostic products. among them, the series of foot-and-mouth disease vaccines include swine foot-and-mouth disease type O, type A bivalent inactivated vaccine (ReO/MYA98/JSCZ/2013 strain + Re-A/WH/09 strain), cattle and sheep foot-and-mouth disease type O, type A bivalent inactivated vaccine (O/MYA98/BY/2010 strain + Re-A/WH/09 strain), swine foot-and mouth disease type A bivalent synthetic vaccine (polypeptide 2700+2800+13 type O synthetic peptide vaccine (polypeptide 2600+2700+2800), etc.

Table 14: The main vaccine products of Shenlian Bio are combed

It is understood that the company has established a "5 + X" technology platform and implemented a diversified product layout. In terms of technology platform, the company has established an inactivated vaccine technology platform, a synthetic peptide vaccine technology platform, a virus-like particle vaccine technology platform and an in vitro diagnostic technology platform, and the mRNA technology platform is gradually being built. In terms of products, the company is currently researching and developing bovine nodular skin disease, classical swine fever, African classical swine fever, Seneca, pseudorabies, porcine reproductive and respiratory syndrome, porcine infectious gastroenteritis, porcine epidemic diarrhea, porcine delta coronavirus disease and other animal disease vaccines and therapeutic biological products, veterinary diagnostic products, etc.

Table 15: Shenlian Biology Research Projects (from 2023 Semi-annual Report)

8. Shanghai Haili Biotechnology Co., Ltd.

Haili Biological was established in 1981. It is a professional veterinary biological products manufacturer integrating R & D, production, sales and service. Its predecessor was Shanghai Songjiang Biological Pharmaceutical Factory. The company is a designated enterprise approved by the Ministry of Agriculture to produce veterinary biological products in Shanghai and a major animal epidemic prevention and control production base established by the Ministry of Agriculture in Shanghai. The company has a complete product line and a complete product structure. It has a total of 23 products in two categories of poultry and livestock. In May 2015, the company was listed on the Shanghai Stock Exchange under the stock code 603718.

Haili Bio is currently showing a development trend of "dual main business" . One is the research and development, production and sales of animal biological products, and the other is actively seeking development in the field of "PICC. Among them, in terms of animal biological products, the company's main products are mainly pig vaccines , and its subsidiary, Yangling Jinhai Biotechnology Co., Ltd., is one of the domestic foot-and-mouth disease vaccine manufacturers and adopts the international advanced suspension culture technology and concentration purification technology to produce high-quality foot-and-mouth disease inactivated vaccine.

Table 16: Hailey Bio's Main Products

Table 17: Hailey Bio's Major Vaccine Product Development Progress (Source: 2023 Semi-Annual Report)

Resources:

[1] First Coverage Report of Pre-family Organism: Research and Development Forges Competition Barriers, Non-plague Vaccines Open up Growth Space. China Merchants Securities. 2024-01-19.

[2] [beijing stock exchange wanlixing] swine fever vaccine leader yongshun biological research and development drive to develop new veterinary drug market. e company. 2023-11-16.

[3] Shenlian Biology: New products are added to the ring market. Only with efficient protection can people be captured. Agricultural treasure book animal husbandry edition. 2024-02-29.

[4] China Pastoral shares: domestic animal insurance industry leader, the ceiling obviously insufficient growth. Sichuan Valley Research Institute. 2023-10-26.

[5] Biological shares -600201-the traditional mobile insurance leader style is still the same, comprehensive innovation and set sail again. SDIC Securities.2024-03-21.

[6] Rip Biology -300119-In-depth Report: Old Things and New Rhymes in Livestock and Poultry Business, Pet Medical Dawn Appearance. Zheshang Securities. 2023-06-08.

[7] Pleco -603566-innovation-driven R & D strength is strong, multi-point breakthrough products can be expected in the future. Shen Wanhongyuan. 2023-09-28.

[8] official websites of various companies, 2023 semi-annual report, Huibo Investment Research, etc.

In order to promote exchanges in the veterinary biological products industry and jointly discuss the latest research and development progress, industrialization status and future development trends in this field, biological products circle will jointly hold the " veterinary biological products research and development and industrialization conference " in Nanjing from April 17-18, 2024 , which is a sub-field professional conference in the new resources conference of China's pharmaceutical industry chain (CBC conference). Researchers in related fields across the country are cordially invited to share the academic event.

Name: Veterinary Biological Products R & D and Industrialization Conference

Time:2024 Year 4 Month 17-18 day (Wednesday - Thursday)

Location: Nanjing International Exhibition Center

Organizer: Biological Products Circle, Antibody Circle, Four-leaf Clover Exhibition, Riding the Wind to the Sea

media support: drug time and space, cell gene research circle

registration method: scan the two-dimensional code below → fill in the form → registration is successful

after obtaining the registration information, the organizing committee will conduct preliminary screening according to the registration information, and further communicate and confirm with the applicants to realize accurate invitation (strict examination and approval).

Conference schedule

Note: The conference schedule is subject to the conference site.

China pharmaceutical industry chain new resources conference (CBC conference) is a cooperation conference that will focus on the new resources of the whole industry chain from "politics, production, learning, research, use, management and investment", which will be held in Nanjing International Exhibition Center from April 16 to 18, 2024. The conference will focus on "new resource docking of the whole industry chain", focusing on investment, project establishment, pre-clinical research and development, clinical research, production, supply chain localization, sales, MAH cooperation, international variety cooperation, company equity cooperation and mergers and acquisitions of the whole industry chain, bringing new resources and business opportunities to Chinese pharmaceutical colleagues. Concurrent meetings under the General Assembly include:

New Resource Conference of Pet Medicine, Food and Health Products

Veterinary Biological Products R & D and Industrialization Conference

Transdermal Technology R & D Production and Registration Opening Year Sharing Meeting

New Opportunities and Progress Sharing Meeting on R & D, Production and Registration of Inhalation Preparations

China Improved New Drugs and Controlled Release Preparations Industry Chain Cooperation Conference

Polypeptide Industry Innovation and Development Conference

New Pharmacopoeia New Accessories and Package Materials Products and Technology Exchange Meeting

new pharmacopoeia new laboratory instruments and consumables practical demonstration exchange meeting

updating in succession ......

biological products WeChat group!

Please specify: Name Research Direction!

Version

Right

Sound

Ming